Plain-English translation of NCT05650632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new investigational medication called for adults with multiple myeloma—a blood cancer—that has either returned after treatment or stopped responding to previous medicines. The study is broken into different groups testing different dosing schedules and delivery methods to find the safest and most effective approach. Researchers want to understand how well this treatment works, what side effects it may cause, and the best way to give it to patients.
Multiple myeloma is a serious blood cancer that often comes back or becomes resistant to standard treatments, leaving patients with limited options. This medication is being developed specifically to help patients whose myeloma no longer responds to available therapies, offering a potential new path forward for those who need it most.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion at a hospital or clinic in 28-day cycles for approximately 3 years. You'll attend regular clinic visits for blood tests, medical check-ups, side effect monitoring, and questionnaires to track how you're doing. Some study groups test whether the medication can be given in an outpatient setting to reduce the burden on your time, while others involve more frequent hospital visits—your doctor will discuss which approach is right for you.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States